Background {#Sec1}
==========

Rheumatologists routinely manage rheumatoid arthritis (RA) using a treat-to-target (T2T) regimens \[[@CR1]\], escalating therapy in patients who fail to reach remission or a low disease activity state \[[@CR2]\]. Management is often initiated with methotrexate alone and then escalation proceeds to combination therapy with conventional disease-modifying anti-rheumatic agents (cDMARDs) and biologic DMARDs (bDMARDs). In New Zealand, cDMARD combinations include triple therapy (methotrexate, sulphasalazine, hydroxychloroquine) and methotrexate/leflunomide, although other options are available. The New Zealand Pharmaceutical Management Agency (PHARMAC), responsible for buying and funding pharmaceuticals, has defined criteria for funding bDMARDs including a trial of three different cDMARD combinations \[[@CR3]\]. For those with an inadequate response to cDMARDs, escalation to methotrexate/anti-tumour necrosis factor (anti-TNF) agents follows and subsequently other bDMARDs. Adequacy of response is usually measured by the DAS28~CRP~ \[[@CR4], [@CR5]\].

MRI is a sensitive imaging modality that can reveal articular inflammation and joint damage \[[@CR6], [@CR7]\]. The OMERACT RA MRI score (RAMRIS) \[[@CR8]\] and the Harvaardsholm tenosynovitis score \[[@CR9]\] can quantify inflammation in a relatively reproducible manner. Studies show that MRI can detect more inflammation than physical examination. Up to 96% of asymptomatic RA patients with normal joints have MRI synovitis and 46% have MRI bone oedema/osteitis \[[@CR10]\]. Krabben et al. \[[@CR11]\] found MRI inflammation in 66% of non-swollen wrist joints in patients with early RA. Severe grades of bone oedema (osteitis) were common in non-swollen joints. We and others have found that osteitis is a predictor of joint erosion \[[@CR12], [@CR13]\]. Although MRI is more sensitive than clinical assessment for detection of joint inflammation and damage, MRI outcomes are not yet part of accepted clinical practice because of feasibility issues including cost and accessibility. It is also not clear whether using the change in MRI inflammation scores to dictate escalation of therapy would lead to better outcomes than using easily administered clinical scores such as the DAS28~CRP~. While clinical trials of bDMARDs including golimumab \[[@CR14]\] and tocilizumab \[[@CR15]\] indicated that clinical responses were associated with improvements in MRI inflammation scores, there is little information comparing clinical and MRI responses to cDMARDs in the T2T "real-world" setting.

The aim of this study was to compare the response in clinical disease activity (DAS28~CRP~) with response in MRI inflammation scores after T2T-dictated escalation of therapy in two groups of RA patients: those escalating from cDMARDs to a different cDMARD combination and those escalating to a combination that includes anti-TNF therapy.

Methods {#Sec2}
=======

Power calculation {#Sec3}
-----------------

Studies exploring the relation between ΔMRI synovitis scores and ΔDAS28~CRP~ \[[@CR7], [@CR16], [@CR17]\] indicated a simple correlation of 0.4. Using a two-sided test at the 5% significance level with 80% power, the required total sample size would be 46 patients. Allowing for 10% dropout, the estimated sample size required was 50. For comparing MRI(i) responses between patients escalating to cDMARDs versus cDMARD/anti-TNFs, sample size was calculated based on the one-sided hypothesis that triple therapy would not be inferior to MTX/anti-TNF. We estimated that with 50 patients per group the study would have 80% power at 5% significance to establish non-inferiority, assuming a between-group difference in change from baseline to 3 months of 2 (SD = 2). Although enrolment was continued for 3 years, only 80 patients with seropositive RA were recruited from rheumatology outpatients' clinics from Auckland and Christchurch, New Zealand between 2014 and 2016. Two cohorts were recruited: Group A included patients on cDMARD therapy (either methotrexate alone or a cDMARD combination), escalating to a different cDMARD combination; and Group B included patients on a cDMARD combination who were escalating to bDMARDs including an anti-TNF agent. Patients were required to have a DAS28~CRP~ ≥ 3.2 at the first clinical visit. Tender joint counts (28 and 68 joints) and swollen joint counts (28 and 66 joints) were performed by trained research nurses and patients filled out questionnaires to assess function. Serum was obtained for inflammatory markers and rheumatoid serology. Written informed consent was obtained from all patients. The study was approved by the Health and Disability Ethics Committees, New Zealand.

MRI scans and scoring {#Sec4}
---------------------

The dominant wrist was scanned using a 3 T scanner (Philips MR Systems Achieve 3 T; Koninklijke Philips Electronics NV, Eindhoven, the Netherlands). An eight-element Philips SENSE 3.0 T Wrist Coil 8 Channel (Invivo Corp, Gainsville, FL, USA) (receive only) was used. The dominant hand in the wrist coil fitted snugly by the patient' s side, palm to body, thumb anteriorly. The field of view included the carpus, distal radioulnar joint (dRUJ) and metacarpal (MC) bases. The following were used: turbo spin echo sequences, T1 weighted (T1w) and T2 weighted (T2w) with fat saturation (FS) using spectral adiabatic inversion recovery (SPAIR) in axial and coronal planes and proton density (PD) coronals (without FS). T1wFS axial and coronal sequences were obtained post intravenous gadolinium diethylenetriamine pentaacetic acid (GdDTPA) at standard dosage (Omniscan (Gadodiamide; 5.0 mmol/10 ml or 2.87 g/10 ml); GE Healthcare, Inc., Princeton, NJ, USA). Synovitis, osteitis and erosions were scored according to RAMRIS \[[@CR8]\] and tenosynovitis in the flexor and extensor compartments \[[@CR9]\]. MRI scan pairs (baseline, 4 months) were scored in known chronological order by one experienced reader (AD), blinded to clinical and X-ray data. Ten scans were selected randomly and rescored 6 months later. The intra-reader reliability was high: ICC (av) = 0.89 (99% CI 0.56--0.97).

X-rays {#Sec5}
------

Plain radiographs of the hands and feet were obtained for all patients on enrolment. They were scored for damage using the Sharp van der Heijde (SvdH) score \[[@CR18]\] by a rheumatologist (ND), blinded to clinical and MRI data.

Statistical analysis {#Sec6}
--------------------

Intra-reader reliability for MRI scores was determined using intraclass correlation coefficients (ICCs). Spearman's correlations were used to examine the association between ΔDAS28~CRP~ and ΔMRI scores. Clinical characteristics for Groups A and B were compared using the chi-square test and median two-sample test. The effect of ΔDAS28~CRP~ and treatment group on ΔMRI(i) were analysed using multiple linear regression adjusting for age, gender, duration, anti-CCP titre and MRI erosion score at baseline. Four patients transited from Group A into Group B, providing eight scan pairs. Apart from analyses investigating baseline patient characteristics where the four patients were included only in their initial Group A, all analyses were performed including these patients in both groups and were conducted using SAS for Windows version 9.4 (SAS Institute Inc., Cary, NC, USA).

Results {#Sec7}
=======

A total of eighty patients were enrolled, fifty-seven in Group A (42 female, 15 male) and 23 patients in Group B (5 female, 18 male) \[[@CR5], [@CR18]\]. Dropout throughout the protocol is summarized in Fig. [1](#Fig1){ref-type="fig"}. One patient began adalimumab for disease control 1 month after enrolment and remained on this bDMARD for 3 months before the second MRI scan and so was switched to Group B. Full clinical and contrast-enhanced MRI data from Visit 1 (baseline) and Visit 2 (4 months) were available for 62 patients. However, 66 scan pairs were available for analysis (including eight pairs from four patients who were sequentially enrolled into Group A then Group B).Fig. 1Clinical and MRI data gathered as patients progressed through the study. IV intravenous, MRI magnetic resonance imaging, TNF tumour necrosis factor, Tx therapy

Clinical characteristics {#Sec8}
------------------------

Patients in Group A and Group B were of similar age and gender but those in Group B had a longer disease duration (Table [1](#Tab1){ref-type="table"}). Consistent with their different places on the T2T escalation ladder, swollen and tender joint counts and disease duration (Visit 1) were lower in Group A than Group B (Table [2](#Tab2){ref-type="table"}). The DAS28~CRP~ was also lower for Group A than Group B: 4.24 vs 5.15 (*p* = 0.007). Interestingly, there was no difference between groups for MRI synovitis or tenosynovitis scores at Visit 1 but total MRI inflammation and osteitis scores were lower in Group A than Group B (*p* = 0.05 and 0.02 respectively) (Table [2](#Tab2){ref-type="table"}). MRI erosion scores were also lower in Group A than Group B: 4 (0--50) and 9 (1--47) respectively (*p* = 0.03). The total SvdH X-ray damage score (Visit 1) was also lower in Group A than Group B: 20.5 (0--217) and 63 (0--209) respectively (*p* = 0.03).Table 1Patient characteristics on enrolmentClinical characteristic at recruitmentTotalGroup AGroup BChi-square *p* value\*(*N* = 80)(*N* = 57)(*N* = 23)Gender Female6075%4273.68%1878.26%0.67 Male2025%1526.32%521.74%Age (months)54.5 (24, 82)53 (24, 81)56 (27, 82)0.22Disease duration (months)36 (3, 408)30 (3, 408)72 (15, 240)0.0014On methotrexate Yes7087.5%4985.96%2191.3%0.72 No1012.5%814.04%28.7%Data presented as *n* (%). Age and disease duration expressed as median (minimum, maximum) values\*Median two-sample test *p* value Table 2Clinical and imaging scores at Visit 1 and Visit 2 (4 months later)Total (*N* = 84)Group A (*N* = 57)Group B (*N* = 27\*)Median two-sample test\
*p* value*N*MedianMinimumMaximum*N*MedianMinimumMaximum*N*MedianMinimumMaximumClinical scores at Visit 1 Tender 28 joints8411128571012827141280.050 Swollen 28 joints8440205740112760200.097 HAQ841.0602.5570.8802.13271.380.132.50.037 DAS28~CRP~844.53.246.64574.243.246.04275.153.366.640.003MRI scores at Visit 1 Synovitis7730951309264090.102 Tendonitis7730155130152630150.931 Osteitis7720345120342630240.021 Erosion7650505040502691470.030 Total inflammation77904551804526131360.050X-ray scores at Visit 1 Erosions62130130425.501122033.501300.001 Total SvdH score6235.502174220.50217206302090.031Clinical scores at Visit 2 Tender 28 joints7260284850282470240.399 Swollen 28 joints721020481020240.5090.337 HAQ720.6302.13480.502240.7502.130.155 DAS28~CRP~723.471.426.64483.281.426.64243.661.425.490.047MRI scores at Visit 2 Synovitis6630942309243080.851 Tendonitis662.50154220152430120.612 Osteitis682034442032243.50340.102 Erosion676050434050249.51470.009 Total inflammation6691534291432491531.000\*Includes the four patients who transitioned from Group A to Group B on escalation of therapy (see text)*DAS28* ~*CRP*~ disease activity score (28 joints) incorporating C-reactive protein, *MRI* magnetic resonance imaging, *SvdH* Sharp van der Heijde, *HAQ* Health assessment questionnaire

Changes in clinical disease activity and MRI inflammation on escalation {#Sec9}
-----------------------------------------------------------------------

Patients' responses were measured by ΔDAS28~CRP~. Both groups improved from Visit 1 to Visit 2 so that ΔDAS28~CRP~ for Group A was −0.94 (−3.30, 1.61) and for Group B was −1.53 (−3.59, 0.56). There was no difference between groups (*p* = 0.45). For Groups A and B, 83.3% and 87.5% respectively had a fall in the DAS28~CRP~ from Visit 1 to Visit 2 indicating clinical improvement, while in 16.7% and 12.5% there was worsening. ΔMRI(i) from Visit 1 to Visit 2 varied between patients but median scores showed little change over 4 months, despite escalation of therapy, and there was no difference between groups. For Group A, ΔMRI(i) median (range) was 0 (−25, 10); for Group B, −1 (−15, 28) (*p* = 0.12). Table [3](#Tab3){ref-type="table"} shows how patients responded in terms of MRI inflammation (total and sub-scores) and MRI erosion score. Only a few showed MRI erosion progression (three patients (6.98%) in Group A and five patients (20.83%) in Group B). The majority had no change in MRI erosion scores (93.0% and 79.17% respectively).Table 3Direction of change for MRI scores from Visit 1 to Visit 2TotalGroup AGroup B*n*%*n*%Change in MRI(i) Decrease1638.11354.1729 Increase1638.1312.519 No change1023.81833.3318 Total422466Change in MRI osteitis Decrease1534.09833.3323 Increase920.4562515 No change2045.451041.6730 Total442468Change in MRI synovitis Decrease1535.711145.8326 Increase921.4314.1710 No change1842.86125030 Total422466Change in MRI tenosynovitis Decrease1228.57937.521 Increase1023.81520.8315 No change2047.621041.6730 Total422466Change in MRI erosion Increase36.98520.838 No change4093.021979.1759 Total432467*MRI* magnetic resonance imaging, *MRI(i)* total MRI inflammation score at the wrist (sum of synovitis, osteitis and tendonitis scores)

Combining groups, there was a weak positive correlation between ΔMRI(i) and ΔDAS28~CRP~ (Spearman's 0.36, *p* = 0.003). Only ΔMRI tenosynovitis correlated with ΔDAS28~CRP~ (Spearman's 0.33, *p* = 0.007); MRI sub-scores for Δosteitis, Δsynovitis and Δerosions did not (Table [4](#Tab4){ref-type="table"}). Multiple linear regression analysis was used to assess the effect of group and ΔDAS28~CRP~ on ΔMRI(i) adjusting for age, gender, duration, anti-CCP titre and MRI erosion score at Visit 1. ΔDAS28~CRP~ was associated with ΔMRI(i) so that for every unit increase in ΔDAS28~CRP~ there was a 1.77-U increase in ΔMRI(i) (*p* = 0.056). Findings are summarized in Fig. [2](#Fig2){ref-type="fig"}.Table 4Correlations between ΔDAS28~CRP~ and ΔMRI scoresChange in MRI scores (over 4 months)Number of observationsSpearman correlation coefficients*p* valueΔtotal MRI(i)66\*0.360.003Δosteitis680.120.33Δsynovitis660.210.09Δtendonitis660.330.007Δerosion67--0.020.87\*Sixty-six scan pairs available, includes eight pairs from the four patients who transitioned from Group A to Group B*DAS28* ~*CRP*~ disease activity score (28 joints) incorporating C-reactive protein, *MRI* magnetic resonance imaging, *MRI(i)* total MRI inflammation score at the wrist (sum of synovitis, osteitis and tendonitis scores) Fig. 2Change in MRI inflammation score (over 4 months) plotted against change in DAS28~CRP~ for each individual patient (labelled A or B according to group). Arrow points to an outlier in Group B (see text). DAS28~CRP~ disease activity score (28 joints) incorporating C-reactive protein, MRI magnetic resonance imaging

Change in MRI score did not differ between groups {#Sec10}
-------------------------------------------------

There was no difference between groups for ΔMRI(i) although the point estimate of the fall in score was numerically greater for Group A (−3.68 (95% CI −6.16 to − 1.20)) than Group B (−0.84 (95% CI −4.27 to 2.60), *p* = 0.18). We did note an outlier in Group B in whom there was a significant fall in the DAS28~CRP~ (from 5.15 (V1) to 3.31 (V2)) despite a marked rise in MRI inflammation scores (from 25 to 53). Data for this patient were excluded in a sensitivity analysis but the difference between groups remained non-significant (*p* = 0.27).

MRI erosion score at V1 was associated with change in MRI(i) {#Sec11}
------------------------------------------------------------

The MRI erosion score (V1) was negatively associated with ΔMRI(i) (parameter estimate −0.28; *p* = 0.0052), so those with higher MRI erosion scores at V1 had a greater fall in MRI(i) from V1 to V2. For every 1-U increase in the V1 erosion score, the MRI(i) score would be estimated to fall from V1 to V2 by 0.28 U. The X-ray erosion score (V1) was not associated with ΔMRI(i) (*p* = 0.79).

Discussion {#Sec12}
==========

This is the first real-world study to investigate the link between changes in clinical disease activity and imaging (MRI) joint inflammation, in a cohort of RA patients undergoing escalation of therapy according to T2T principles. In this setting, the clinical target is most often a low disease activity state or complete remission (DAS28~CRP~ ≤ 1.9). It has been suggested that more stringent imaging targets should be used so that patients are treated aggressively, aiming to reach a state where there is no imaging evidence of inflammation at all \[[@CR19]\]. MRI scanning can inform about inflammation affecting different tissues including synovium (synovitis), bone (osteitis) and tendon sheaths/tendons (tenosynovitis). We found a significant but relatively weak association between change in clinical disease activity as measured by the DAS28~CRP~ over the 4-month period after escalation of therapy, and change in the total MRI inflammation score. The only MRI sub-score separately associated with ΔDAS28~CRP~ was the ΔMRI tendonitis score, although there was a trend towards an association with the ΔMRI synovitis score. These findings are consistent with observations by Krabben et al. \[[@CR11]\], who found in their analysis of 1790 joints in 179 patients that synovitis and tenosynovitis on MRI were independently associated with clinical swelling. In that study, MRI inflammation was most often observed at the wrist, validating our choice of site for MRI scanning.

Although we did observe an association between change in clinical disease activity and change in MRI inflammation scores, it was obvious from inspection of the data that many individual patients improved clinically over the 4 months after treatment escalation, with only minor changes in their MRI inflammation scores. In some instances MRI inflammation worsened despite clinical improvement. Could this be due to the much greater sensitivity of MRI for detecting joint inflammation? Clinicians are familiar with high-grade clinical joint inflammation manifesting as Virchow's triad of redness, swelling and tenderness, while lesser degrees may only be detectable as pain on movement. MRI can detect inflammation below the clinical threshold by revealing thickened synovium and tenosynovium, which often enhance post contrast, reflecting increased vascularity. However, if MRI inflammation simply represents the low end of the inflammatory spectrum, one might expect a closer correlation between clinical and imaging observations than we have found. A ceiling effect for MRI inflammation scores could be part of the explanation. Thus, a severely inflamed wrist joint might achieve a very high MRI inflammation score, which remains high even when joint swelling and tenderness have subsided. A period of 4 months might also have been insufficient time for MRI(i) to fall in some patients \[[@CR20]\]. Another explanation for the relative disparity between changes in clinical and MRI scores is that they capture slightly different information. Clinical disease activity scores incorporate (through joint tenderness) an assessment of pain and this is missing from the MRI inflammation score. The MRI inflammation score incorporates osteitis, which is not directly detectable clinically. Additionally, low-grade synovitis may occur in normal individuals, especially older people \[[@CR21]\], and this could contribute to background "noise" within the MRI inflammation score. In this study we have used the DAS28~CRP~ as a "gold standard" against which changes in MRI inflammation were compared, but this measure has its own shortcomings and in some studies the physician global assessment is a better predictor of clinical decision-making \[[@CR22]\].

Another possible explanation for the relatively poor correlation between change in MRI inflammation scores and change in the DAS28~CRP~ might be that MRI scans in this study imaged one region only, the dominant wrist, while the DAS28~CRP~ reflected disease activity at 28 joints. We were able to retrieve joint count data and found evidence for tenderness and/or swelling at the scanned wrist in 71.2% of patients at Visit 1 and 47% at Visit 2. Thus, the wrist was quite frequently involved. How well do MRI scans of the wrist reflect, or in other words act as a surrogate marker for, overall rheumatoid disease activity? The evidence for this is indirect. In an early study by McQueen et al. \[[@CR12]\], MRI wrist bone oedema (osteitis) scores were predictive of radiographic erosion progression at the hands and feet 6 years later. In 2014, Baker et al. \[[@CR20]\] reported a very similar result for MRI osteitis and synovitis from one hand (wrist and MCPs), which were again highly predictive of radiographic progression in the joints of the hands and feet 1 and 2 years later. In 2017, Glinatsi et al. \[[@CR23]\] published a post-hoc analysis of clinical trial data from the CIMESTRA/OPERA cohorts and concluded that MRI-assessed inflammation at the wrist (rather than at the MCP joints) was the most important parameter reflecting physical function, pain and global assessment of disease activity in early RA. Thus, although MRI scanning of one joint area may potentially suffer from "sampling error", there is evidence that the wrist is a particularly informative region.

One of the aims of the study was to compare MRI parameters between patients escalating from one cDMARD combination to another cDMARD combination (Group A) and patients escalating to anti-TNF therapy/cDMARDs (Group B). Group B patients, who were further up the T2T escalation ladder, differed from Group A patients in that they had higher scores for MRI erosion and osteitis at their first visit. Interestingly, there were no differences between groups in terms of synovitis or tendonitis. This is consistent with the known association between MRI osteitis and erosion progression in RA \[[@CR12], [@CR13]\], and emphasizes that bone inflammation (osteitis) may be qualitatively and prognostically different from soft tissue joint inflammation (synovitis and tenosynovitis). Molenaar et al. \[[@CR24]\] observed that clinically relevant damage progression can occur in patients in prolonged remission. Thus, MRI may have an important role in the detection of osteitis and prediction of damage progression; a role that cannot be duplicated by clinical assessment alone. Very few of our patients demonstrated MRI erosion progression over 4 months but longer follow-up would be required to determine whether those with clinically normal joints but high levels of osteitis had a worse erosive outcome. We did not find evidence for a greater reduction in MRI inflammation scores in those receiving anti-TNF therapy than those on cDMARDs. Although Groups A and B cannot be directly compared because of differences in disease duration, this supports the observations of O'Dell et al. \[[@CR25]\] who showed equivalent clinical improvement in patients treated with triple therapy and those receiving anti-TNF/methotrexate therapy. Our findings also go some way towards validating the NZ PHARMAC escalation protocol that requires patients to have first tried cDMARD therapy before escalating to more costly bDMARD options.

What are the implications of our findings for the treating clinician? T2T regimens using clinical targets have been profoundly effective in limiting the progression of joint damage and disability in RA patients on cDMARD and bDMARD regimens \[[@CR26]\]. If the goal posts are shifted to more stringent imaging targets, what is the evidence for better outcomes? The OMERACT group have studied this by looking for evidence of a "safe level" of MRI inflammation below which damage progression did not to occur, using MRI data from several RA clinical trial cohorts \[[@CR27]\]. Gandjbakhch et al. identified an "acceptable MRI inflammatory activity state" as a RAMRIS synovitis score below 6. In these individuals, radiographic progression rarely occurred. As yet there is no evidence that clinical or functional outcomes are better in such patients. Our study has indicated considerable disparity between clinical disease activity and MRI joint inflammation, and has emphasized that the goal of complete imaging resolution of inflammation is far off in the majority of real-world patients. Is it appropriate to treat these individuals more aggressively? Issues of feasibility, cost and patient acceptability mean that clinical goals are probably to be preferred over MRI goals at least in the short term. Whether ultrasound can step into the gap remains an open question \[[@CR28]\]. Both the ARCTIC \[[@CR29]\] and the TaSER \[[@CR30]\] studies have recently investigated whether ultrasound imaging can improve patient outcomes if used by clinicians to inform decision-making. Both studies concluded that an ultrasound-driven T2T strategy was not associated with significantly better clinical or imaging outcomes than a DAS28-driven strategy. Further large prospective studies of this type are now needed for MRI scanning.

Our study has a number of limitations. Firstly, the study was observational. It was not possible to stipulate what disease-suppressing therapies could be given and the associations we observed could have been influenced by individual DMARDs. We considered stratifying patients according to therapy but there were many combinations of cDMARDs used and groups would have been too small for useful comparison. However, we did establish that a similar proportion of Group A and Group B patients were taking methotrexate at their first visit. Secondly, although we found no difference between groups in clinical or MRI responses to therapy, this comparison was flawed by insufficient statistical power and also by the fact that the groups differed in terms of disease duration and radiographic erosions at baseline \[[@CR31]\]. Despite extending enrolment by a year we did not reach the numbers required to satisfy the original power calculation. Nevertheless, our comparative clinical and MRI data do shed light on what is actually happening in terms of joint inflammation in rheumatoid patients undergoing escalation of therapy in routine rheumatology practice, and should be of help to clinicians working towards the aim of improving quality of life in their patients.

Conclusions {#Sec13}
===========

Full clinical and MRI data were available at two time points, before and 4 months after a change of therapy, in 66 out of 80 RA patients undergoing real-world T2T escalation. There was no or minimal change in the median MRI inflammation score over 4 months, despite clinical improvement. There was no difference in the MRI inflammation response between those escalating to a different cDMARD regimen and those escalating to a cDMARD/anti-TNF regimen. For the entire group there was a significant correlation between the change in the DAS28~CRP~ and the change in the MRI inflammation score (Spearman's 0.36, *p* = 0.003), but this was relatively weak. These results suggest that MRI outcomes should not be adopted to direct T2T escalation as clinically driven strategies are already successful in improving patient outcomes. A randomized controlled trial comparing MRI-driven and DAS-driven strategies is needed.
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